

# The Medical Letter®

## On Drugs and Therapeutics

---

Published by The Medical Letter, Inc. • 145 Huguenot Street, New Rochelle, NY 10801 • A Nonprofit Publication

---

**IN THIS ISSUE** (starts on next page)

**In Brief: Clopidogrel and Omeprazole ..... p 93**

### Important Copyright Message

The Medical Letter® publications are protected by US and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with US and international copyright laws and these terms and conditions of The Medical Letter, Inc.

**For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)  
or call customer service at: 800-211-2769**

---

**FORWARDING OR COPYING IS A VIOLATION OF US AND INTERNATIONAL COPYRIGHT LAWS**

# The Medical Letter<sup>®</sup>

## On Drugs and Therapeutics

---

Published by The Medical Letter, Inc. • 145 Huguenot Street, New Rochelle, NY 10801 • A Nonprofit Publication

---

Volume 52 (Issue 1352)  
November 29, 2010

[www.medicalletter.org](http://www.medicalletter.org)

### IN BRIEF

---

#### Clonidogrel and Omeprazole

Use of a proton pump inhibitor (PPI) to protect against gastrointestinal (GI) bleeding in patients taking the antiplatelet agent clonidogrel (*Plavix*) may interfere with the activation of clonidogrel and diminish its antiplatelet effect, increasing the risk of cardiovascular events.<sup>1</sup> A randomized, placebo-controlled trial (COGENT) has found that use of the PPI omeprazole in patients taking clonidogrel in addition to aspirin decreased the incidence of GI bleeding without increasing the risk of a cardiovascular event, but the number of cardiovascular events was small and the formulation of omeprazole was atypical.<sup>2</sup> The FDA in the same issue of the same journal cautioned against concluding from the results of COGENT that concurrent use of clonidogrel and omeprazole is safe.<sup>3</sup>

To some extent, all PPIs reduce the enzymatic activity of CYP2C19, which is thought to be mainly responsible for the bioactivation of clonidogrel. Omeprazole is a strong inhibitor of CYP2C19; pantoprazole (*Protonix*, and others) appears to have less effect on CYP2C19 and not to attenuate the antiplatelet effect of clonidogrel.<sup>4-6</sup> Medical Letter consultants believe that patients at risk for upper GI bleeding who take clonidogrel should also take a PPI, but not omeprazole. Until more data become available on other PPIs, pantoprazole would be a reasonable choice.

1. PPI interactions with clonidogrel revisited. *Med Lett Drugs Ther* 2009; 51:13.
2. DL Bhatt et al. Clonidogrel with or without omeprazole in coronary artery disease. *N Engl J Med* 2010; 363:1909.
3. MR Southworth and R Temple. Interaction of clonidogrel and omeprazole. *N Engl J Med* 2010; 363:1977.
4. DJ Angiolillo et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clonidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. *Clin Pharmacol Ther* 2010; Sept 15 epub.
5. T Cuisset et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clonidogrel maintenance dose: the PACA (Proton Pump Inhibitors And Clonidogrel Association) prospective randomized study. *J Am Coll Cardiol* 2009; 54:1149.
6. H Neubauer et al. Pantoprazole does not influence the antiplatelet effect of clonidogrel – a whole blood aggregometry study after coronary stenting. *J Cardiovasc Pharmacol* 2010; 56:91.

The Medical Letter®  
On Drugs and Therapeutics

**EDITOR IN CHIEF:** Mark Abramowicz, M.D.  
**EXECUTIVE EDITOR:** Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School  
**EDITOR:** Jean-Marie Pflomm, Pharm.D.  
**ASSISTANT EDITORS, DRUG INFORMATION:** Susan M. Daron, Pharm.D., Blaine M. Houst, Pharm.D., Corinne E. Zanone, Pharm.D.  
**CONSULTING EDITOR:** Brinda M. Shah, Pharm.D.  
**CONTRIBUTING EDITORS:**  
Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons  
Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School  
Eric J. Epstein, M.D., Albert Einstein College of Medicine  
Jules Hirsch, M.D., Rockefeller University  
David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre  
Richard B. Kim, M.D., University of Western Ontario  
Hans Meinertz, M.D., University Hospital, Copenhagen  
Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine  
Dan M. Roden, M.D., Vanderbilt University School of Medicine  
F. Estelle R. Simons, M.D., University of Manitoba  
Jordan W. Smoller, M.D., Sc.D., Harvard Medical School  
Neal H. Steigbigel, M.D., New York University School of Medicine  
Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weil Medical College of Cornell University  
**SENIOR ASSOCIATE EDITORS:** Donna Goodstein, Amy Faucard  
**ASSOCIATE EDITOR:** Cynthia Macapagal Covey  
**EDITORIAL FELLOW:** Esperance A.K. Schaefer, M.D., M.P.H., Massachusetts General Hospital, Harvard Medical School  
**MANAGING EDITOR:** Susie Wong  
**ASSISTANT MANAGING EDITOR:** Liz Donohue  
**PRODUCTION COORDINATOR:** Cheryl Brown

**EXECUTIVE DIRECTOR OF SALES:** Gene Carbona  
**FULFILLMENT & SYSTEMS MANAGER:** Cristine Romatowski  
**DIRECTOR OF MARKETING COMMUNICATIONS:** Joanne F. Valentino  
**VICE PRESIDENT AND PUBLISHER:** Yosef Wissner-Levy

Founded in 1959 by  
Arthur Kallet and Harold Aaron, M.D.

**Copyright and Disclaimer:** The Medical Letter is an independent nonprofit organization that provides health care professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter is supported solely by subscription fees and accepts no advertising, grants or donations.

No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy or omission.

**Subscription Services**

<b>Mailing Address:</b> The Medical Letter, Inc. 145 Huguenot St. Ste. 312 New Rochelle, NY 10801-7537	<b>Subscriptions (US):</b> 1 year - \$98; 2 years - \$189; 3 years - \$279. \$49.00 per year for students, interns, residents and fellows in the US and Canada.
<b>Customer Service:</b> Call: 800-211-2769 or 914-235-0500 Fax: 914-632-1733 Web Site: www.medicalletter.org E-mail: custserv@medicalletter.org	<b>E-mail site license inquiries to:</b> info@medicalletter.org or call 800-211-2769 x315. Special fees for bulk subscriptions. Special classroom rates are available. Back issues are \$12 each. Major credit cards accepted.
<b>Permissions:</b> To reproduce any portion of this issue, please e-mail your request to: permissions@medicalletter.org	

Copyright 2010. ISSN 1523-2859